KR100361933B1
(ko)
*
|
1993-09-08 |
2003-02-14 |
라 졸라 파마슈티칼 컴파니 |
화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
|
US6458953B1
(en)
*
|
1998-12-09 |
2002-10-01 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising carbamate linkages
|
US7666400B2
(en)
*
|
2005-04-06 |
2010-02-23 |
Ibc Pharmaceuticals, Inc. |
PEGylation by the dock and lock (DNL) technique
|
ES2327606T3
(es)
|
2000-01-10 |
2009-11-02 |
Maxygen Holdings Ltd |
Conjugados de g-csf.
|
ES2325877T3
(es)
|
2000-02-11 |
2009-09-23 |
Bayer Healthcare Llc |
Moleculas de tipo factor vii o viia.
|
US6586398B1
(en)
*
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
DK1311285T4
(en)
*
|
2000-05-15 |
2017-07-24 |
Hoffmann La Roche |
Liquid pharmaceutical composition containing an erythropoietin derivative
|
AU2001268228A1
(en)
|
2000-06-08 |
2001-12-17 |
La Jolla Pharmaceutical Company |
Multivalent platform molecules comprising high molecular weight polyethylene oxide
|
MXPA03000311A
(es)
*
|
2000-07-12 |
2004-12-13 |
Gryphon Therapeutics Inc |
Produccion y uso de moduladores de receptor de quimiocina.
|
US7030218B2
(en)
*
|
2000-09-08 |
2006-04-18 |
Gryphon Therapeutics |
Pseudo native chemical ligation
|
US7118737B2
(en)
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
EP1333036B1
(en)
*
|
2000-10-16 |
2009-01-21 |
Chugai Seiyaku Kabushiki Kaisha |
Peg-modified erythropoietin
|
CN100528235C
(zh)
|
2000-12-20 |
2009-08-19 |
霍夫曼-拉罗奇有限公司 |
红细胞生成素共轭物
|
EP1471871B1
(en)
|
2001-02-02 |
2007-05-02 |
Ortho-McNeil Pharmaceutical, Inc. |
Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
|
WO2002074806A2
(en)
|
2001-02-27 |
2002-09-26 |
Maxygen Aps |
New interferon beta-like molecules
|
US20040077835A1
(en)
*
|
2001-07-12 |
2004-04-22 |
Robin Offord |
Chemokine receptor modulators, production and use
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
US7696163B2
(en)
|
2001-10-10 |
2010-04-13 |
Novo Nordisk A/S |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
US6818613B2
(en)
|
2001-11-07 |
2004-11-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Aqueous sustained-release formulations of proteins
|
US7473680B2
(en)
|
2001-11-28 |
2009-01-06 |
Neose Technologies, Inc. |
Remodeling and glycoconjugation of peptides
|
WO2003045423A1
(en)
|
2001-11-28 |
2003-06-05 |
Ortho-Mcneil Pharmaceutical, Inc. |
Erythropoietin dosing regimen for treating anemia
|
WO2003078959A2
(en)
|
2002-03-11 |
2003-09-25 |
Ortho Mcneil Pharmaceutical, Inc |
Methods for shp1 mediated neuroprotection
|
CA2490360A1
(en)
|
2002-06-21 |
2003-12-31 |
Novo Nordisk Health Care Ag |
Pegylated factor vii glycoforms
|
EP1534269B1
(en)
*
|
2002-07-19 |
2013-10-30 |
The General Hospital Corporation |
Oxime conjugates and methods for their formation and use
|
US20040091961A1
(en)
*
|
2002-11-08 |
2004-05-13 |
Evans Glen A. |
Enhanced variants of erythropoietin and methods of use
|
AU2003303636B2
(en)
*
|
2002-12-26 |
2010-08-05 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
|
GEP20084486B
(en)
*
|
2002-12-26 |
2008-09-25 |
Mountain View Pharmaceuticals |
Polymer conjugates of interferon-beta with enhanced biological potency
|
EP1616003A4
(en)
|
2002-12-30 |
2007-06-20 |
Gryphon Therapeutics Inc |
WATER-SOLUBLE THIOESTER AND SELENOESTER COMPOUNDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
|
CA2519092C
(en)
|
2003-03-14 |
2014-08-05 |
Neose Technologies, Inc. |
Branched water-soluble polymers and their conjugates
|
US20070026485A1
(en)
|
2003-04-09 |
2007-02-01 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
EP1613261A4
(en)
|
2003-04-09 |
2011-01-26 |
Novo Nordisk As |
INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
|
US20050107297A1
(en)
|
2003-05-12 |
2005-05-19 |
Holmes Christopher P. |
Novel poly(ethylene glycol) modified compounds and uses thereof
|
NZ543934A
(en)
|
2003-05-12 |
2008-06-30 |
Affymax Inc |
Novel spacer moiety for poly (ethylene glycol)-modified peptide-based compounds
|
EP1625156B1
(en)
*
|
2003-05-12 |
2012-09-19 |
Affymax, Inc. |
Peptides that bind to the erythropoietin receptor
|
EA010095B1
(ru)
*
|
2003-05-12 |
2008-06-30 |
Афимакс, Инк. |
Новые пептиды, которые связываются с рецептором эритропоэтина
|
US7074755B2
(en)
*
|
2003-05-17 |
2006-07-11 |
Centocor, Inc. |
Erythropoietin conjugate compounds with extended half-lives
|
CN1826131A
(zh)
*
|
2003-05-30 |
2006-08-30 |
森托科尔公司 |
利用转谷氨酰胺酶形成新的促红细胞生成素缀合物
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
WO2005035565A1
(en)
|
2003-10-10 |
2005-04-21 |
Novo Nordisk A/S |
Il-21 derivatives
|
EP2641611A3
(en)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Combination therapy
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
ES2445948T3
(es)
|
2003-11-24 |
2014-03-06 |
Ratiopharm Gmbh |
Eritropoyetina glicopegilada
|
US7368169B2
(en)
*
|
2003-12-01 |
2008-05-06 |
Rutgers, The State University Of New Jersey |
Hydrazide compounds with angiogenic activity
|
ES2560657T3
(es)
|
2004-01-08 |
2016-02-22 |
Ratiopharm Gmbh |
Glicosilación con unión en O de péptidos G-CSF
|
US20070105770A1
(en)
*
|
2004-01-21 |
2007-05-10 |
Novo Nordisk A/S |
Transglutaminase mediated conjugation of peptides
|
CN1909930B
(zh)
|
2004-01-21 |
2015-12-16 |
诺和诺德医疗保健公司 |
转谷氨酰胺酶介导的肽的接合
|
BRPI0507169A
(pt)
|
2004-02-02 |
2007-06-26 |
Ambrx Inc |
polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
|
MXPA06014307A
(es)
*
|
2004-06-08 |
2007-03-12 |
Alza Corp |
Preparacion de conjugados macromoleculares por reaccion de condensacion de cuatro componentes.
|
JP2008503217A
(ja)
|
2004-06-18 |
2008-02-07 |
アンブレツクス・インコーポレイテツド |
新規抗原結合ポリペプチド及びそれらの使用
|
WO2006010143A2
(en)
|
2004-07-13 |
2006-01-26 |
Neose Technologies, Inc. |
Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
EP1799249A2
(en)
|
2004-09-10 |
2007-06-27 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
DK2586456T3
(en)
|
2004-10-29 |
2016-03-21 |
Ratiopharm Gmbh |
Conversion and glycopegylation of fibroblast growth factor (FGF)
|
EP1814910A4
(en)
*
|
2004-11-11 |
2009-04-29 |
Affymax Inc |
NEW AT ERYTHROPOIETIN RECEPTOR BINDING PEPTIDES
|
WO2006062685A2
(en)
*
|
2004-11-11 |
2006-06-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
ES2821832T3
(es)
*
|
2004-11-12 |
2021-04-27 |
Bayer Healthcare Llc |
Modificación de FVIII dirigida al sitio
|
EP1836314B1
(en)
|
2004-12-22 |
2012-01-25 |
Ambrx, Inc. |
Modified human growth hormone
|
JP5425398B2
(ja)
|
2004-12-22 |
2014-02-26 |
アンブレツクス・インコーポレイテツド |
非天然アミノ酸及びポリペプチドを含む組成物、非天然アミノ酸及びポリペプチドに関連する方法並び非天然アミノ酸及びポリペプチドその使用
|
CA2594561C
(en)
|
2004-12-22 |
2014-12-23 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
CA2590429C
(en)
|
2004-12-22 |
2014-10-07 |
Ambrx, Inc. |
Compositions of aminoacyl-trna synthetase and uses thereof
|
NZ555206A
(en)
|
2004-12-22 |
2010-09-30 |
Ambrx Inc |
Methods for expression and purification of recombinant human growth hormone
|
JP4951527B2
(ja)
|
2005-01-10 |
2012-06-13 |
バイオジェネリックス アーゲー |
糖peg化顆粒球コロニー刺激因子
|
WO2006089228A2
(en)
*
|
2005-02-16 |
2006-08-24 |
Nektar Therapeutics Al, Corporation |
Conjugates of an epo moiety and a polymer
|
WO2007010552A2
(en)
*
|
2005-03-17 |
2007-01-25 |
Serum Institute Of India Limited |
N- terminal peg conjugate of erythropoietin
|
EP2314320A2
(en)
|
2005-04-05 |
2011-04-27 |
Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. |
Method for shielding functional sites or epitopes on proteins
|
US20070154992A1
(en)
|
2005-04-08 |
2007-07-05 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
EP1888098A2
(en)
|
2005-05-25 |
2008-02-20 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin formulations
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
CN103030690A
(zh)
|
2005-06-03 |
2013-04-10 |
Ambrx公司 |
经改良人类干扰素分子和其用途
|
US7919461B2
(en)
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7550433B2
(en)
*
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
AU2006257792A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Mdrna, Inc. |
Transmucosal delivery of peptide derivatives
|
EP1893632B1
(en)
|
2005-06-17 |
2015-08-12 |
Novo Nordisk Health Care AG |
Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
CN101268098A
(zh)
*
|
2005-08-30 |
2008-09-17 |
诺沃-诺迪斯克保健股份有限公司 |
聚乙二醇化生长激素的液体制剂
|
US20080171696A1
(en)
*
|
2005-10-21 |
2008-07-17 |
Avigenics, Inc. |
Pharmacodynamically enhanced therapeutic proteins
|
US20070092486A1
(en)
*
|
2005-10-21 |
2007-04-26 |
Avigenics, Inc. |
Glycolated and glycosylated poultry derived therapeutic proteins
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
US20090018029A1
(en)
|
2005-11-16 |
2009-01-15 |
Ambrx, Inc. |
Methods and Compositions Comprising Non-Natural Amino Acids
|
CN101062407A
(zh)
|
2006-04-29 |
2007-10-31 |
中国科学院上海生命科学研究院 |
促红细胞生成素在预防或治疗视网膜损伤中的用途
|
US7851438B2
(en)
*
|
2006-05-19 |
2010-12-14 |
GlycoFi, Incorporated |
Erythropoietin compositions
|
RU2008145084A
(ru)
|
2006-05-24 |
2010-06-27 |
Ново Нордиск Хелс Кеа Аг (Ch) |
Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
|
CA2655188A1
(en)
|
2006-07-07 |
2008-01-10 |
Novo Nordisk Health Care Ag |
New protein conjugates and methods for their preparation
|
WO2008011633A2
(en)
|
2006-07-21 |
2008-01-24 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
ES2529234T3
(es)
*
|
2006-08-04 |
2015-02-18 |
Prolong Pharmaceuticals, LLC |
Eritropoyetina modificada
|
JP5840345B2
(ja)
|
2006-09-08 |
2016-01-06 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
修飾ヒト血漿ポリペプチドまたは修飾ヒトFc足場タンパク質ならびにこれらの利用
|
AU2007292892B9
(en)
|
2006-09-08 |
2013-02-28 |
Ambrx, Inc. |
Hybrid suppressor tRNA for vertebrate cells
|
WO2008030614A2
(en)
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Suppressor trna transcription in vertebrate cells
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
WO2008094275A1
(en)
|
2007-01-30 |
2008-08-07 |
New York University |
Peptides for treatment of conditions associated with nitric oxide
|
CA2676820A1
(en)
*
|
2007-01-31 |
2008-08-07 |
Affymax, Inc. |
Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
|
KR101476472B1
(ko)
|
2007-03-30 |
2015-01-05 |
암브룩스, 인코포레이티드 |
변형된 fgf-21 폴리펩티드 및 그 용도
|
CA2682897C
(en)
|
2007-04-03 |
2016-11-22 |
Biogenerix Ag |
Methods of treatment using glycopegylated g-csf
|
JP2010525821A
(ja)
|
2007-05-02 |
2010-07-29 |
アンブルックス,インコーポレイテッド |
修飾IFNβポリペプチドおよびこれらの使用
|
MX2009013259A
(es)
|
2007-06-12 |
2010-01-25 |
Novo Nordisk As |
Proceso mejorado para la produccion de azucares de nucleotidos.
|
WO2009003188A2
(en)
*
|
2007-06-27 |
2008-12-31 |
Cedars-Sinai Medical Center |
N-terminal specific chemical labeling for proteomics applications
|
DK2217265T3
(en)
|
2007-11-20 |
2017-07-03 |
Ambrx Inc |
Modified insulin polypeptides and their use
|
CN101456911A
(zh)
*
|
2007-12-12 |
2009-06-17 |
江苏豪森药业股份有限公司 |
促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
|
WO2009073977A1
(en)
*
|
2007-12-13 |
2009-06-18 |
Biovectra Inc. |
Polypeptides modified by protein trans-splicing technology
|
CN103694337B
(zh)
|
2008-02-08 |
2016-03-02 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
PL2257311T3
(pl)
|
2008-02-27 |
2014-09-30 |
Novo Nordisk As |
Koniugaty cząsteczek czynnika VIII
|
EP3225248B1
(en)
|
2008-07-23 |
2023-06-07 |
Ambrx, Inc. |
Modified bovine g-csf polypeptides and their uses
|
EP2157432A1
(en)
*
|
2008-08-15 |
2010-02-24 |
Qiagen GmbH |
Method for analysing a complex sample by mass spectrometry
|
KR101732054B1
(ko)
|
2008-09-26 |
2017-05-02 |
암브룩스, 인코포레이티드 |
비천연 아미노산 복제 의존성 미생물 및 백신
|
AU2009296397B2
(en)
|
2008-09-26 |
2012-11-08 |
Ambrx Inc. |
Modified animal erythropoietin polypeptides and their uses
|
JP5751641B2
(ja)
|
2009-05-06 |
2015-07-22 |
ヤンセン バイオテツク,インコーポレーテツド |
メラノコルチン受容体結合コンジュゲート
|
PL2459224T3
(pl)
*
|
2009-07-27 |
2017-08-31 |
Baxalta GmbH |
Koniugaty białka związanego z krzepnięciem krwi
|
NZ600363A
(en)
|
2009-12-21 |
2014-07-25 |
Ambrx Inc |
Modified porcine somatotropin polypeptides and their uses
|
EP2805964A1
(en)
|
2009-12-21 |
2014-11-26 |
Ambrx, Inc. |
Modified bovine somatotropin polypeptides and their uses
|
JP6148013B2
(ja)
|
2010-03-05 |
2017-06-14 |
リグショスピタレト |
補体活性化のキメラ抑制分子
|
US20120135912A1
(en)
|
2010-05-10 |
2012-05-31 |
Perseid Therapeutics Llc |
Polypeptide inhibitors of vla4
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
DK2605789T3
(da)
|
2010-08-17 |
2019-09-16 |
Ambrx Inc |
Modificerede relaxinpolypeptider og anvendelser deraf
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
CN102652836A
(zh)
*
|
2011-03-03 |
2012-09-05 |
华中科技大学同济医学院附属协和医院 |
靶向释药的抗癌蛋白质或多肽聚合物前药及其制备方法
|
AR087020A1
(es)
|
2011-07-01 |
2014-02-05 |
Bayer Ip Gmbh |
Polipeptidos de fusion de relaxina y usos de los mismos
|
CN103747807B
(zh)
|
2011-07-05 |
2016-12-07 |
比奥阿赛斯技术有限公司 |
P97‑抗体缀合物和使用方法
|
KR102172897B1
(ko)
|
2012-06-08 |
2020-11-02 |
서트로 바이오파마, 인크. |
부위-특이적 비-천연 아미노산 잔기를 포함하는 항체, 그의 제조 방법 및 그의 사용 방법
|
WO2014004639A1
(en)
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
US9932565B2
(en)
|
2012-07-31 |
2018-04-03 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
PL3584255T3
(pl)
|
2012-08-31 |
2022-05-16 |
Sutro Biopharma, Inc. |
Modyfikowane aminokwasy zawierające grupę azydkową
|
CN104870423A
(zh)
|
2012-11-16 |
2015-08-26 |
加利福尼亚大学董事会 |
用于蛋白质化学修饰的pictet-spengler连接反应
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
CN102935236B
(zh)
*
|
2012-11-21 |
2015-08-26 |
武汉平华生物医药科技有限公司 |
一种具有p-糖蛋白抑制功能的抗肿瘤前药
|
BR112015022416A2
(pt)
|
2013-03-13 |
2017-10-24 |
Bioasis Technologies Inc |
fragmentos de p97 e seus usos
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
AU2014312190A1
(en)
|
2013-08-28 |
2016-02-18 |
Bioasis Technologies Inc. |
CNS-targeted conjugates of antibodies
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
EA201690780A1
(ru)
|
2013-10-15 |
2016-08-31 |
Сиэтл Дженетикс, Инк. |
Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
|
JP6745218B2
(ja)
|
2013-11-27 |
2020-08-26 |
レッドウッド バイオサイエンス, インコーポレイテッド |
ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
|
UY36370A
(es)
|
2014-10-24 |
2016-04-29 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Polipéptidos fgf-21 modificados y sus usos
|
SG11201804268RA
(en)
|
2015-12-04 |
2018-06-28 |
Seattle Genetics Inc |
Conjugates of quaternized tubulysin compounds
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
EP3433278A4
(en)
|
2016-03-25 |
2019-11-06 |
Seattle Genetics, Inc. |
PROCESS FOR THE PREPARATION OF PEGYLATED MEDICINE LINKS AND INTERMEDIATES THEREOF
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
ES2963839T3
(es)
|
2017-02-08 |
2024-04-02 |
Bristol Myers Squibb Co |
Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
|
WO2018175994A1
(en)
|
2017-03-24 |
2018-09-27 |
Seattle Genetics, Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
CN111094462A
(zh)
|
2017-12-26 |
2020-05-01 |
贝克顿·迪金森公司 |
深紫外线可激发的水溶剂化聚合物染料
|
WO2019191482A1
(en)
|
2018-03-30 |
2019-10-03 |
Becton, Dickinson And Company |
Water-soluble polymeric dyes having pendant chromophores
|
TW202015740A
(zh)
|
2018-06-07 |
2020-05-01 |
美商西雅圖遺傳學公司 |
喜樹鹼結合物
|
EP3813867A1
(en)
|
2018-07-22 |
2021-05-05 |
Bioasis Technologies Inc. |
Treatment of lymmphatic metastases
|
JP7441826B2
(ja)
|
2018-09-11 |
2024-03-01 |
アンブルックス,インコーポレイテッド |
インターロイキン-2ポリペプチド抱合物およびその使用
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
CN109400695B
(zh)
*
|
2018-10-31 |
2020-06-30 |
中南大学湘雅医院 |
一种多肽的修饰方法及应用
|
JP2022520792A
(ja)
|
2019-02-12 |
2022-04-01 |
アンブルックス,インコーポレイテッド |
抗体-tlrアゴニストコンジュゲートを含有する組成物、その方法、及び使用
|
WO2021067861A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Camptothecin peptide conjugates
|
CA3174114A1
(en)
|
2020-03-11 |
2021-09-16 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and methods of use thereof
|
MX2022012621A
(es)
|
2020-04-10 |
2023-01-18 |
Seagen Inc |
Enlazadores de variantes de carga.
|
US20210355468A1
(en)
|
2020-05-18 |
2021-11-18 |
Bioasis Technologies, Inc. |
Compositions and methods for treating lewy body dementia
|
US20210393787A1
(en)
|
2020-06-17 |
2021-12-23 |
Bioasis Technologies, Inc. |
Compositions and methods for treating frontotemporal dementia
|
JP2023538071A
(ja)
|
2020-08-20 |
2023-09-06 |
アンブルックス,インコーポレイテッド |
抗体-tlrアゴニストコンジュゲート、その方法及び使用
|
TW202246242A
(zh)
|
2021-01-15 |
2022-12-01 |
美商西健公司 |
免疫調節抗體藥物結合物
|
AR124812A1
(es)
|
2021-02-03 |
2023-05-10 |
Seagen Inc |
Conjugados y compuestos inmunoestimulantes
|
CA3213805A1
(en)
|
2021-04-03 |
2022-10-06 |
Feng Tian |
Anti-her2 antibody-drug conjugates and uses thereof
|
WO2022251850A1
(en)
|
2021-05-28 |
2022-12-01 |
Seagen Inc. |
Anthracycline antibody conjugates
|
EP4155349A1
(en)
|
2021-09-24 |
2023-03-29 |
Becton, Dickinson and Company |
Water-soluble yellow green absorbing dyes
|
WO2023083919A1
(en)
|
2021-11-09 |
2023-05-19 |
Tubulis Gmbh |
Conjugates comprising a phosphorus (v) and a camptothecin moiety
|
WO2023083900A1
(en)
|
2021-11-09 |
2023-05-19 |
Tubulis Gmbh |
Conjugates comprising a phosphorus (v) and a drug moiety
|
US20230381321A1
(en)
|
2022-03-17 |
2023-11-30 |
Seagan Inc., |
Camptothecin conjugates
|
WO2023215740A1
(en)
|
2022-05-06 |
2023-11-09 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
WO2024007016A2
(en)
|
2022-07-01 |
2024-01-04 |
Beckman Coulter, Inc. |
Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
|
WO2024030577A1
(en)
|
2022-08-03 |
2024-02-08 |
Seagen Inc. |
Immunostimulatory anti-pd-l1-drug conjugates
|
EP4321522A1
(en)
|
2022-08-12 |
2024-02-14 |
Seagen Inc. |
Cytotoxic compounds and conjugates thereof
|
WO2024044327A1
(en)
|
2022-08-26 |
2024-02-29 |
Beckman Coulter, Inc. |
Dhnt monomers and polymer dyes with modified photophysical properties
|